Olipass Corp
244460
Company Profile
Business description
Olipass Corp is a South Korea based biotechnology company engaged in developing its platform OliPass PNA which focuses on introducing cationic lipid moiety onto nucleobase. Its pipeline products include SC Injection, Hyper Cholesterolemia, Chemo/Radio-sensitizer, and Type II Diabetes among others.
Contact
16-4, 16 Beon-gil, Dongbaek Jungang-ro
Ace Dongbaek Tower 20th Floor
Giheung-gu
Yongin17015
KORT: +82 3180608200
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
57
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,959.70 | 106.00 | 1.35% |
| CAC 40 | 7,273.12 | 168.32 | 2.37% |
| DAX 40 | 20,954.83 | 580.73 | 2.85% |
| Dow JONES (US) | 40,524.79 | 312.08 | 0.78% |
| FTSE 100 | 8,134.34 | 170.16 | 2.14% |
| HKSE | 21,417.40 | 502.71 | 2.40% |
| NASDAQ | 16,831.48 | 107.03 | 0.64% |
| Nikkei 225 | 33,982.36 | 396.78 | 1.18% |
| NZX 50 Index | 12,093.93 | 13.61 | -0.11% |
| S&P 500 | 5,405.97 | 42.61 | 0.79% |
| S&P/ASX 200 | 7,748.60 | 102.10 | 1.34% |
| SSE Composite Index | 3,262.81 | 24.58 | 0.76% |